Skip to content

Integrated Imaging System for In Vivo Visualization of Free Flap Perfusion Using Indocyanine Dye

Evaluation of an Integrated Imaging System (SmartGoggles) for in Vivo Visualization of Free Flap Perfusion Using Indocyanine Green Fluorescent Dye

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03625765
Enrollment
0
Registered
2018-08-10
Start date
2019-11-22
Completion date
2024-12-31
Last updated
2024-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Reconstruction

Keywords

Indocyanine green, SmartGoggles

Brief summary

The purpose of this study is to determine if the integrated imaging goggle (Smart Goggles) is as good as or better than current technology used to assess tissue perfusion (the extent of blood flow to the tissue) in certain types of breast reconstruction procedures. The participants will be asked to participate in the study if they are scheduled to have a breast reconstruction procedure using a technique that involves transferring abdominal skin and tissues to the affected side of the chest. This technique is known as a breast reconstruction with a Deep Inferior Epigastric Artery Perforator (DIEP) flap. In this pilot study, the investigators are testing the feasibility of a new device, the Integrated Imaging Goggle system (also called Smart Goggles) as a surgical aid to differentiate between tissue with adequate blood flow and tissue without adequate blood flow by comparing measurements of fluorescence in blood vessels with current technology, the SPY-Elite system. In this study, researchers will test how quickly and accurately the fluorescent dye used to identify adequate blood flow is detected by Smart Goggles compared to the SPY Elite system.

Detailed description

The objective is to demonstrate the sensitivity of the SmartGoggles for detection of Indocyanine (ICG) fluorescence within fasciocutaneous flap. The investigators will characterize the sensitivity of the SmartGoggles device relative to a previously validated device (the SPY Elite system). The investigator's primary endpoint will compare the ICG transit time (the time needed for ICG to first appear in flap after intravenous injection) detected by the SmartGoggles and the SPY Elite system. As a secondary endpoint, the investigators will compare the ICG accumulation curve and fluorescence intensity generated from each device, measured on the same region of interests (ROI). Finally, the study team will compare perfusion margin characteristics (the area between regions of well-perfused and hypoperfused tissue) as assessed by the Goggles and the SPY Elite system. Study Design This is an unpowered pilot study to determine the sensitivity of the new SmartGoggles device for detection of ICG fluorescence in free flaps in a clinical setting. The investigators have chosen to examine ICG as the contrast agent because this agent is FDA-approved and is regularly used for evaluation of tissue perfusion. The team has chosen to use DIEP free flaps as the clinical target because these flaps are relatively large and will provide adequate surface area for measurement of fluorescent margins and comparison of fluorescence between the Goggles and SPY Elite systems. This study will enroll 25 patients. After signing consent form all patients will undergo standard of care preoperative and postoperative evaluations. Investigators will perform one ICG angiography per patient: intraoperatively after designing and harvesting the flap. All measurements will be taken by SmartGoggles and SPY Elite systems.

Interventions

DEVICESmartGoggles

the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.

Sponsors

Case Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing unilateral DIEP flap breast reconstruction * Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

* Pregnant women * Patients with severe hepatic insufficiency * Patients with a history of allergic reactions or know hypersensitivity to ICG and iodide

Design outcomes

Primary

MeasureTime frameDescription
ICG transit time detected by the SmartGoggles and the SPY Elite system.At the end of surgery - 1 dayThe time needed for ICG to first appear in flap after intravenous injection

Secondary

MeasureTime frameDescription
Difference in the ICG accumulation curve and fluorescence intensity generated from each device, measured on the same region of interestsAt the end of surgery - 1 daycompared between SmartGoggles and the SPY Elite System using a one-sided non-inferiority analysis based on a paired t-test.
Difference in square area of perfusion as detected by ICG angiography under the SmartGoggles and SPY Elite systemsAt the end of surgery - 1 dayThis perfusion margin characteristic provides a difference in detection by the two imaging systems

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026